Literature DB >> 12590232

Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease.

Antonio Tursi1, Giovanni Brandimarte, Gian Marco Giorgetti.   

Abstract

GOALS: Although anti-tissue transglutaminase antibodies (anti-tTG) are effective for celiac disease (CD) routine laboratory screening, there are no studies evaluating correlation between degree of intestinal damage and positivity to anti-tTG. Since recent studies showed that anti-gliadin (AGA) and anti-endomysium (EMA) antibodies are ineffective in diagnosing mild gluten-sensitive enteropathy, the aim of this study was to evaluate the prevalence of anti-tTG in different degrees of intestinal damage of celiac patients and whether there is a correlation between serum value of anti-tTG and the degree of histologic damage. STUDY: We studied 119 consecutive adult patients affected by CD (47 men and 72 women; mean age, 28 years; range, 22-51 years). All patients were stratified for histologic damage according to Marsh classification, and in all of them an anti-tTG evaluation was performed.
RESULTS: Marsh I lesions were present in 13 patients (10.92%), Marsh II in 24 anti-tTG (20.16%), Marsh IIIa in 27 anti-tTG (22.68%), Marsh IIIb in 31 anti-tTG (26.05%) and Marsh IIIc in 24 anti-tTG (20.16%). Anti-tTG positivity was ranging from 1 of 13 anti-tTG (7.69%) in Marsh I lesions to 23 of 24 anti-tTG (95.83%) in Marsh IIIc lesions respectively ( P< 0.005), while mean serum value of anti-tTG ranged from 3.61 (range, 0.7-9.2) UA/mL in Marsh I lesions to 7.3 (range, 1-25.1), 18.5 (range, 1.8-56.2), 36 (range, 3.7-83.5) and 74.95 (range, 6.5-257) UA/mL in Marsh II, IIIb and IIIc lesions respectively (P < 0.005).
CONCLUSIONS: Our study showed that anti-tTG prevalence and their mean serum value was higher in celiacs with severe enteropathy (Marsh IIIb-c lesions) than in those showing slight enteropathy (Marsh I-IIIa). So, serologic tests without histologic evaluation may underestimate the real prevalence of CD and there is the risk of delaying the diagnosis of CD in patients who run an increased risk of deficiencies, non-malignant conditions and malignancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590232     DOI: 10.1097/00004836-200303000-00007

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  37 in total

1.  Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy.

Authors:  Julian A Abrams; Beverly Diamond; Heidrun Rotterdam; Peter H R Green
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

2.  Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease.

Authors:  Shadi Rashtak; Michael W Ettore; Henry A Homburger; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03-04       Impact factor: 11.382

Review 3.  Celiac disease in the East and the West: Bridging the gaps between the guidelines and their implementation in daily practice is mandatory.

Authors:  Anmol Dhawan; Ashish Agarwal; Chris J Mulder; Govind K Makharia
Journal:  Indian J Gastroenterol       Date:  2019-06

4.  Resolution of metabolic syndrome after following a gluten free diet in an adult woman diagnosed with celiac disease.

Authors:  Alvaro García-Manzanares; Alfredo J Lucendo; Sonia González-Castillo; Jesús Moreno-Fernández
Journal:  World J Gastrointest Pathophysiol       Date:  2011-06-15

Review 5.  Serum markers in the clinical management of celiac disease.

Authors:  Marlou Adriaanse; Daniel A Leffler
Journal:  Dig Dis       Date:  2015-04-22       Impact factor: 2.404

6.  Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods.

Authors:  S Rashtak; M W Ettore; H A Homburger; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

7.  Prevalence of celiac disease in adult patients with refractory functional dyspepsia: value of routine duodenal biopsy.

Authors:  Emiliano Giangreco; Cinzia D'agate; Carmelo Barbera; Lidia Puzzo; Giuseppe Aprile; Pietro Naso; Giacomo Bonanno; Francesco-Paolo Russo; Alessandra Nicoletti; Salvatore Incarbone; Giuseppe Trama; Antonio Russo
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

8.  IgA anti-actin antibodies in children with celiac disease: comparison of immunofluorescence with Elisa assay in predicting severe intestinal damage.

Authors:  Elena Bazzigaluppi; Barbara Parma; Giulia M Tronconi; Patrizia Corsin; Luca Albarello; Stefano Mora; Graziano Barera
Journal:  Ital J Pediatr       Date:  2010-03-18       Impact factor: 2.638

9.  Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines.

Authors:  Jiri Nevoral; Radana Kotalova; Ondrej Hradsky; Vera Valtrova; Kristyna Zarubova; Jan Lastovicka; Eva Neubertova; Marketa Trnkova; Jiri Bronsky
Journal:  Eur J Pediatr       Date:  2013-11-15       Impact factor: 3.183

10.  Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis.

Authors:  Ramin Shakeri; Farhad Zamani; Rasoul Sotoudehmanesh; Afsaneh Amiri; Mehdi Mohamadnejad; Fereydoun Davatchi; Ali Mohammadi Karakani; Reza Malekzadeh; Farhad Shahram
Journal:  BMC Gastroenterol       Date:  2009-06-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.